TP53 and endometrial cancer: Oncogene changes, such as K-ras mutation, c-erbB2/neu gene amplification, and cyclin D1 and p53 overexpression have also been observed in tamoxifen-related endometrial cancers (Esteller et al. 1997; Esteller et al. 1999; Boyd, 1996).